BLTE

Rating buyAI Memo

Belite Bio

As of 2026-01-17/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-01-17 • Model: RankAlpha Sentiment AI

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

buy

Confidence

medium

Horizon

—

Key catalyst

Planned clinical readout (assumed window end) • 2026-10-01

Base target: $165 / p=60% prob

Biggest risk

Adverse or inconclusive DRAGON data, regulatory setbacks, or dilutive financing could compress valuation toward the analyst low (85.0), reflecting binary event risk and limited liquidity.

Invalidation

Break below $85 or thesis failure.

What would change my mind?

A favorable DRAGON readout or a strategic partnership materially re-rates the stock toward the analyst high (200.0), improving commercial visibility and justifying upside beyond the modest base.

Research note

Recommendation

buy

Confidence

medium

As of

2026-01-17

Base target

$165

p=60%

Bull target

$200

p=25%

Bear target

$85

p=15%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Investor update / cash-runway disclosure
Partnership / licensing or commercialization progress
A favorable DRAGON readout or a strategic partnership materially re-rates the stock toward the analyst high (200.0), improving commercial visibility and justifying upside beyond the modest base.

BearKey bullets

Insufficient cash / dilutive financing
Negative clinical readout
Partnering or commercialization failure

WatchKey bullets

Planned clinical readout (assumed window end)

Summary

High-level snapshot

Recommendation

buy

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $165 (p=60%)

Target spread vs base: +21% / -49%

Scenario probabilities

Bull Target: $200 (p=25%)Base Target: $165 (p=60%)Bear Target: $85 (p=15%)

Commentary

Cautiously positive: analyst median sits above the anchor but the wide high/low dispersion signals binary event risk. Near-term focus on operational updates and clinical timelines implies event-driven volatility [#SERP-2][#SERP-1].

As of 2026-01-17 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

A favorable DRAGON readout or a strategic partnership materially re-rates the stock toward the analyst high (200.0), improving commercial visibility and justifying upside beyond the modest base.

Bear Case

Adverse or inconclusive DRAGON data, regulatory setbacks, or dilutive financing could compress valuation toward the analyst low (85.0), reflecting binary event risk and limited liquidity.

Drivers

Scannable catalysts and supporting factors

Investor update / cash-runway disclosure
Partnership / licensing or commercialization progress

Human Analyst Targets

External snippets for comparison only; verify at source.

Unverified externalLast fetched 2026-01-17Source quality: external scrape

External snippets are unverified; treat as directional signals only. Always confirm with the original provider.

Inline RA est

Provider

serper

Median (USD)

$165.29

Range (USD)

$85.00 - $200.00

Count

Query: Belite Bio Inc ADR (BLTE) analyst consensus price target high low average

Belite Bio ADR (BLTE) Stock Forecast & Price Target - Investing.com
Search result #1
According to projections from 7 analysts, the average 12-month price target for Belite Bio ADR is 185.28571, with a high estimate of 200 and a low estimate of ...
Open source
Belite Bio, Inc. ADR (BLTE) Stock Forecast, Price Targets ... - TipRanks
Search result #2
The average price target is $170.86 with a high forecast of $200.00 and a low forecast of $85.00. The average price target represents a 4.18% change from the ...
Extracted: $170.86, $200.00, $85.00Open source
What is the current Price Target and Forecast for Belite Bio (BLTE)
Search result #3
The forecasts for Belite Bio, Inc. Sponsored ADR (BLTE) range from a low of $140 to a high of $200. The average price target represents a increase of $12.97 ...
Extracted: $140.00, $200.00, $12.97Open source
Belite Bio Inc. ADR Analyst Estimates - BLTE - MarketWatch
Search result #4
Stock Price Targets. High, $200.00. Median, $190.50. Low, $140.00. Average, $184.33. Current Price, $165.29. Yearly Numbers. Estimates. BLTE will report 2025 ...
Extracted: $200.00, $190.50, $140.00, $184.33, $165.29Open source
Belite Bio, Inc (BLTE) Stock Price, News, Quote & History
Search result #5
View More. Analyst Price Targets. 140.00 Low. 185.29 Average. 155.11 Current. 200.00 High. Analyst Recommendations. Strong Buy. Buy. Hold. Underperform. Sell ...
Open source
BLTE - Belite Bio ADR Stock - Displayed [30 Analyst Price Targets]
Search result #6
Highest price target for BLTE is $185, Lowest price target is $132, average price target is $157. Most recent stock forecast was given by YI CHEN from HC ...
Extracted: $185.00, $132.00, $157.00Open source

Scenarios

Bull Target (Scenario probability)

$200 / p=25% prob

Base Target (Scenario probability)

$165 / p=60% prob

Bear Target (Scenario probability)

$85 / p=15% prob

Analysis 2026-01-17 · RankAlpha Sentiment AI

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-10-01
Planned clinical readout (assumed window end)
Assumed end-of-window for a pivotal/Phase 2 readout; date is estimated conservatively and noted as an assumption in absence of a public date [#PR-2026-10-01].
Prob 30.00% • Move 40.00% • Priced-in 20.00%

Short-term Catalysts

Next few weeks

Investor update / cash-runway disclosure
2026-04-17
Company update on cash runway or near-term operational milestones; no public date available so set to short-horizon default (as_of_date +90 days) [#IR-Update].
Prob 60% • Move 8% • Priced-in 50%

Long-term Catalysts

Months to a year

Partnership / licensing or commercialization progress
2027-01-17
Potential business development or commercialization progress assumed over a multi‑quarter horizon; date set to long default (as_of_date +365 days) as conservative estimate [#BD-2027-01-17].
Prob 20% • Move 60% • Priced-in 10%

Risks

Insufficient cash / dilutive financing
Negative clinical readout
Partnering or commercialization failure
Regulatory delay or adverse guidance

Peers

Symbol	Summary
SRPT	Rare-disease biotech; comparable on commercialization and regulatory execution risk.
EDIT	Clinical-stage, event-driven company where binary readouts create sharp valuation swings.
NTLA	Advanced/gene-therapy peer with high upside potential but significant technical and regulatory execution risk.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment AI
Human targets: serper
Targets query: Belite Bio Inc ADR (BLTE) analyst consensus price target high low average
Analysis date: 2026-01-17

Loading AI feed…

Symbol

Summary

SRPT

Rare-disease biotech; comparable on commercialization and regulatory execution risk.

EDIT

Clinical-stage, event-driven company where binary readouts create sharp valuation swings.

NTLA

Advanced/gene-therapy peer with high upside potential but significant technical and regulatory execution risk.